Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

• Sponsor: Lawrence Fong (Other)
• Overall Status: Terminated
• CT.gov ID: NCT02506114
• Collaborator: Bavarian Nordic (Industry)
• Enrollment: 15
• Location: 1
• Arms: 3
• Actual Duration (Months): 42.5
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

This is a multicentered, open label, randomized phase II trial of PROSTVAC or ipilimumab or the combination of PROSTVAC and ipilimumab as neoadjuvant therapy in patients with localized prostate cancer. Eligible patients will be randomized to PROSTVAC monotherapy (Arm A), ipilimumab monotherapy (Arm B), or combination therapy with both PROSTVAC and ipilimumab (Arm C), prior to RP. In arms A and C, PROSTVAC-V will be administered subcutaneously as the primary vaccine on Day 1, which will be followed 2 weeks later with a series of 2 PROSTVAC-F subcutaneous administrations, given 3 weeks apart. In arms B and C, ipilimumab will be administered twice, at a dose of 3mg/kg, 3 weeks apart. In the combination arm, ipilimumab administration will coincide with the PROSTVAC-F administration. In arm B, ipilimumab will begin on Day 1. In all three arms, radical prostatectomy (RP) will occur 21 days, or three weeks, following final treatment administration of PROSTVAC or ipilimumab. No further therapy will be administered on study following RP.

Condition or Disease	Intervention/Treatment	Phase
Prostatic Neoplasms	Biological: PROSTVAC V/F; Drug: Ipilimumab	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 15 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy
• Actual Study Start Date: Oct 6, 2016
• Actual Primary Completion Date: Apr 22, 2020
• Actual Study Completion Date: Apr 22, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm A: PROSTVAC-V/F PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.	Biological: PROSTVAC V/F; PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
Experimental: Arm B: Ipilimumab Monotherapy Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.	Drug: Ipilimumab
Experimental: Arm C: Combined PROSTVAC-V/F + Ipilimumab PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.	Biological: PROSTVAC V/F; PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.; Drug: Ipilimumab

Outcome Measures

Primary Outcome Measures

1. Proportion of Participants With Positive CD3+ T Cell Immune Response [Up to 2 years]

   The proportion of participants who demonstrated a positive response following neoadjuvant therapy as measured by change from baseline in CD3+ T cell infiltration within prostate tumor tissue by immunohistochemistry (IHC) assessment following treatment will be reported. The change in the number of CD3+ T cell infiltration within prostate tissue between the biopsy and radical prostatectomy (RP) specimen will be quantified using immunohistochemistry (IHC),with a positive result if there is >=2 fold increase in the number of CD3+T cell infiltration.

Secondary Outcome Measures

1. Proportion of Participants With Any Positive Change in Immunologic Infiltration (CD3) [Up to 2 years]

   The proportion of participants who demonstrated any change in the number of infiltrating T cells/μm2 of CD3 within the prostatic tumor tissue from the diagnostic core biopsy specimens to the post treatment prostatectomy tissue specimens will be assessed, based upon IHC analysis following neoadjuvant PROSTVAC, ipilimumab, or the combination of the two treatments.

2. Proportion of Participants With Any Positive Change in Circulating Effector T Cells [Up to 2 years]

   The proportion of participants who demonstrated any change in the number of circulating effector T cells/μm2 within the prostatic tumor tissue from the diagnostic core biopsy specimens to the post treatment prostatectomy tissue specimens will be assessed, based upon IHC analysis following neoadjuvant PROSTVAC, ipilimumab, or the combination by flow cytometry assessment of peripheral blood mononuclear cells

3. Proportion of Participants With a Positive Change in Regulatory T Cells [Up to 2 years]

   The proportion of participants who demonstrated a change in the number of Regulatory T Cells/μm2 within the prostatic tumor tissue from the diagnostic core biopsy specimens to the post treatment prostatectomy tissue specimens will be assessed, based upon IHC analysis following neoadjuvant PROSTVAC, ipilimumab, or the combination by flow cytometry assessment of peripheral blood mononuclear cells

4. Number of Participants With Treatment-Related Adverse Events [Up to 2 years]

   Safety analyses will be performed for all participants having received at least one dose of study drug. The investigator will use the NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4.03 for reporting the number of participants with treatment-related, non-hematologic, adverse events and modified criteria for hematologic adverse events defined as having an attribute of possible, probable, or definite by toxicity and treatment group.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Inclusion Criteria:

For a subject to be eligible for participation in this study, all of the following criteria must be satisfied:

1. Patients must have histologically confirmed adenocarcinoma of the prostate without previous therapy for prostate cancer (PC).

• Treatment-naïve AND

• Undergoing radical prostatectomy (RP) as initial, locally definitive therapy for PC and

• Eligible for RP in a 3 month timeframe AND

• Consentable for RP

1. Subject's archival prostate biopsy specimen is available, and subject consents to provide tissue for study endpoint analysis. The prostate biopsy slides or blocks must be available prior to starting any study treatment.

2. Age ≥ 18 years

3. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. Subject has adequate organ function, defined as:

• White blood cell (WBC) count ≥ 3,000/microliter (mcL)

• Absolute neutrophil count (ANC) ≥ 1,500/mcL

• Platelet count ≥ 100,000/mcL

• Hemoglobin (Hgb) ≥ 10.0 g/dL

• Creatinine ≤ 1.5x institutional upper limit of normal (ULN)

• Total bilirubin ≤ 1.5 x institutional ULN

• Alanine aminotransferase (ALT) ≤ 1.5 x institutional ULN

• Aspartate aminotransferase (AST) ≤ 1.5 x institutional ULN

• Prothrombin time (PT) /International Normalized Ratio (INR), partial thromboplastin time (PTT) within institutional ULN

1. No known history of human immunodeficiency virus (HIV) 1 and 2, human T-cell lymphotropic virus (HTLV)-I/II, and Hepatitis B and C.

2. Ability to understand a written informed consent document, and the willingness to sign it.

3. Because of the unknown potential risk to a gamete and/or developing embryo from these investigational therapies, subjects must agree to use adequate contraception (i.e. barrier method) for the duration of study participation, and for three months after discontinuing therapy.

Exclusion Criteria:

A subject will not be eligible for participation in this study if any of the following criteria apply.

1. Subject's biopsy specimen reveals neuroendocrine or small cell features.

2. Subject has any evidence of metastatic disease (pre-operative staging will be undertaken per urologic standard of care) as deemed by the Investigator.

3. Subject has prior use of any hormones, including luteinizing hormone-releasing hormone (LHRH) agonists, ketoconazole, antiandrogens (such as bicalutamide, flutamide, or nilutamide), or 5-α-reductase inhibitors.

4. Subject has prior use of any anti-cancer treatment or product, such as PC-SPES (or any other PC-x product: PC-HOPE, PC-CARE, PC-PLUS, etc).

5. Subject has received prior radiation therapy or chemotherapy for prostate cancer.

6. Chronic administration (defined as daily or every other day for continuous use >14 days) of systemic corticosteroids within 28 days of the first planned dose off PROSTVAC-V/F. Use of inhaled steroids, nasal sprays, and topical creams for small body areas are allowed.

7. Active atopic dermatitis or skin condition that disrupts the epidermis

8. Inflammatory eye disease requiring steroid treatment

9. History of prior solid organ or bone marrow transplant

10. Previous history of hypersensitivity to eggs or allergy or untoward reaction to prior vaccinia (smallpox) vaccination.

11. Splenectomy

12. Subject, or subject's close household contacts (defined as those who share housing or have close physical contact) have any of the following conditions during the screening and/or treatment periods:

• active or a history of atopic dermatitis, eczema or other eczematoid skin disorders that disrupt the epidermis

• other acute, chronic or exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne or other open rashes or wounds) until condition resolves

• pregnant or nursing

• immunodeficient or immunosuppressed (by disease or therapy), including HIV infection

1. Subject's close household contacts include children less than the age of three

2. History of, or active autoimmune disease (e.g., autoimmune neutropenia, thrombocytopenia, or hemolytic anemia, systemic lupus erythematosis, Sjogren´s syndrome, scleroderma, myasthenia gravis, Goodpasture´s syndrome, Addison´s disease, Hashimotos´s thyroiditis, or Graves disease) as determined by the treating medical oncologist.

• Persons with vitiligo are not excluded.

• Diabetics are not excluded if the condition is well controlled:

1. Hemoglobin A1C < 7.0, and

2. No evidence of end-organ damage due to diabetes, such as diabetic retinopathy, nephropathy, or neuropathy

3. Persons with type 2 diabetes are not excluded since this is not an autoimmune disease, and do not need to meet these criteria.

• Persons with hypothyroidism are not excluded if condition is well controlled, and condition is due to a non-autoimmune etiology.

1. Subject has received treatment with any investigational immunotherapy within 2 years prior to study screening or has received treatment with any other investigational product within 28 days prior to study screening.

2. Subject has participated in any previous study involving PROSTVAC-V/F, Sipuleucel-T or ipilimumab, regardless of whether the subject received PROSTVAC-V/F, Sipuleucel-T or ipilimumab.

3. Subject has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PROSTVAC-V/F or ipilimumab.

4. Subject has a history of stage III or greater cancer, excluding prostate cancer. Subjects with a history of basal or squamous cell skin cancers are allowed, provided that the subject was adequately treated and is disease-free at the time of study screening. Subjects with a history of stage I or II cancer must have been adequately treated and been disease-free for ≥ 3 years prior to study screening.

5. Subject has any uncontrolled, concurrent illness including, but not limited to the following: ongoing or active infection (bacterial, viral, or fungal), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, stroke or myocardial infarction within 6 months, or psychiatric illness that would limit compliance with study requirements.

6. Subject requires any medical intervention(s) or has any other condition(s) that, in the Investigator's opinion, will 1) make the administration of PROSTVAC or ipilimumab hazardous, 2) obscure the interpretation of adverse events (AEs), 3) compromise adherence with study requirements, or 4) otherwise compromise the study's objectives.

7. Subject has high-risk features (e.g., based on Gleason score, PSA, clinical stage, % positive biopsies), and the treating physician feels the subject should undergo radical prostatectomy sooner than planned within the protocol.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of California, San Francisco	San Francisco	California	United States	94143

Sponsors and Collaborators

• Lawrence Fong
• Bavarian Nordic

Investigators

• Principal Investigator: Lawrence Fong, MD, University of California, San Francisco

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Jul 10, 2018

More Information

Publications

None provided.

• Responsible Party: Lawrence Fong, Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco
• ClinicalTrials.gov Identifier: NCT02506114
• Other Study ID Numbers: 14559; NCI-2017-01679
• First Posted: Jul 22, 2015
• Last Update Posted: Nov 24, 2021
• Last Verified: Oct 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Lawrence Fong, Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco: prostate
• Additional relevant MeSH terms: Prostatic Neoplasms; Ipilimumab

Study Results

Participant Flow

Arm/Group Title	Arm A: PROSTVAC-V/F	Arm B: Ipilimumab Montherapy	Arm C: Combined PROSTVAC-V/F + Ipilimumab
Arm/Group Description	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.	Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
Period Title: Overall Study
STARTED	5	4	6
COMPLETED	5	4	6
NOT COMPLETED	0	0	0

Baseline Characteristics

Arm/Group Title	Arm A: PROSTVAC-V/F	Arm B: Ipilimumab Monotherapy	Arm C: Combined PROSTVAC-V/F + Ipilimumab	Total
Arm/Group Description	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.	Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.	Total of all reporting groups
Overall Participants	5	4	6	15
Age, Customized (Count of Participants)
50-59 years old	1 20%	0 0%	2 33.3%	3 20%
60-69 years old	1 20%	2 50%	3 50%	6 40%
70-79 years old	3 60%	2 50%	1 16.7%	6 40%
Sex: Female, Male (Count of Participants)
Female	0 0%	0 0%	0 0%	0 0%
Male	5 100%	4 100%	6 100%	15 100%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	2 33.3%	2 13.3%
Not Hispanic or Latino	5 100%	4 100%	4 66.7%	13 86.7%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%
Black or African American	0 0%	0 0%	0 0%	0 0%
White	5 100%	3 75%	4 66.7%	12 80%
More than one race	0 0%	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	1 25%	2 33.3%	3 20%
Region of Enrollment (participants) [Number]
United States	5 100%	4 100%	6 100%	15 100%
Total Gleason Score (Count of Participants)
Gleason Score = 6	0 0%	0 0%	1 16.7%	1 6.7%
Gleason Score = 7	3 60%	1 25%	4 66.7%	8 53.3%
Gleason Score = 8	0 0%	0 0%	0 0%	0 0%
Gleason Score = 9	2 40%	3 75%	1 16.7%	6 40%

Outcome Measures

1. Primary Outcome

Title	Proportion of Participants With Positive CD3+ T Cell Immune Response
Description	The proportion of participants who demonstrated a positive response following neoadjuvant therapy as measured by change from baseline in CD3+ T cell infiltration within prostate tumor tissue by immunohistochemistry (IHC) assessment following treatment will be reported. The change in the number of CD3+ T cell infiltration within prostate tissue between the biopsy and radical prostatectomy (RP) specimen will be quantified using immunohistochemistry (IHC),with a positive result if there is >=2 fold increase in the number of CD3+T cell infiltration.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Few participants had evaluable labs for this outcome.

Arm/Group Title	Arm A: PROSTVAC-V/F	Arm B: Ipilimumab Monotherapy	Arm C: Combined PROSTVAC-V/F + Ipilimumab
Arm/Group Description	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.	Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
Measure Participants	2	3	3
Number [proportion of participants]	0 0%	0.33 8.3%	0 0%

2. Secondary Outcome

Title	Proportion of Participants With Any Positive Change in Immunologic Infiltration (CD3)
Description	The proportion of participants who demonstrated any change in the number of infiltrating T cells/μm2 of CD3 within the prostatic tumor tissue from the diagnostic core biopsy specimens to the post treatment prostatectomy tissue specimens will be assessed, based upon IHC analysis following neoadjuvant PROSTVAC, ipilimumab, or the combination of the two treatments.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Few participants had evaluable labs for this outcome.

Arm/Group Title	Arm A: PROSTVAC-V/F	Arm B: Ipilimumab Monotherapy	Arm C: Combined PROSTVAC-V/F + Ipilimumab
Arm/Group Description	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.	Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
Measure Participants	2	3	3
Number [proportion of participants]	0 0%	0.667 16.7%	0 0%

3. Secondary Outcome

Title	Proportion of Participants With Any Positive Change in Circulating Effector T Cells
Description	The proportion of participants who demonstrated any change in the number of circulating effector T cells/μm2 within the prostatic tumor tissue from the diagnostic core biopsy specimens to the post treatment prostatectomy tissue specimens will be assessed, based upon IHC analysis following neoadjuvant PROSTVAC, ipilimumab, or the combination by flow cytometry assessment of peripheral blood mononuclear cells
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm A: PROSTVAC-V/F	Arm B: Ipilimumab Monotherapy	Arm C: Combined PROSTVAC-V/F + Ipilimumab
Arm/Group Description	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.	Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
Measure Participants	5	4	6
Number [proportion of participants]	0.8 16%	1.0 25%	0.8333 13.9%

4. Secondary Outcome

Title	Proportion of Participants With a Positive Change in Regulatory T Cells
Description	The proportion of participants who demonstrated a change in the number of Regulatory T Cells/μm2 within the prostatic tumor tissue from the diagnostic core biopsy specimens to the post treatment prostatectomy tissue specimens will be assessed, based upon IHC analysis following neoadjuvant PROSTVAC, ipilimumab, or the combination by flow cytometry assessment of peripheral blood mononuclear cells
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm A: PROSTVAC-V/F	Arm B: Ipilimumab Monotherapy	Arm C: Combined PROSTVAC-V/F + Ipilimumab
Arm/Group Description	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.	Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
Measure Participants	5	4	6
Number [proportion of participants]	0.4 8%	1.0 25%	1.0 16.7%

5. Secondary Outcome

Title	Number of Participants With Treatment-Related Adverse Events
Description	Safety analyses will be performed for all participants having received at least one dose of study drug. The investigator will use the NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4.03 for reporting the number of participants with treatment-related, non-hematologic, adverse events and modified criteria for hematologic adverse events defined as having an attribute of possible, probable, or definite by toxicity and treatment group.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm A: PROSTVAC-V/F	Arm B: Ipilimumab Monotherapy	Arm C: Combined PROSTVAC-V/F + Ipilimumab
Arm/Group Description	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.	Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
Measure Participants	5	4	6
Fatigue	1 20%	1 25%	0 0%
Fever	1 20%	0 0%	0 0%
Injection site reaction	2 40%	0 0%	1 16.7%
Lipase increased	1 20%	0 0%	0 0%
Pruritus	0 0%	1 25%	0 0%
Dizziness	0 0%	0 0%	1 16.7%
Skin and subcutaneous tissue disorders - Other	0 0%	0 0%	1 16.7%

Adverse Events

Time Frame	Up to 2 years
Arm/Group Title	Arm A: PROSTVAC-V/F		Arm B: Ipilimumab Monotherapy		Arm C: Combined PROSTVAC-V/F + Ipilimumab
Arm/Group Description	PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.		Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.		PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
All Cause Mortality
	Arm A: PROSTVAC-V/F		Arm B: Ipilimumab Monotherapy		Arm C: Combined PROSTVAC-V/F + Ipilimumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/5 (0%)		0/4 (0%)		0/6 (0%)
Serious Adverse Events
	Arm A: PROSTVAC-V/F		Arm B: Ipilimumab Monotherapy		Arm C: Combined PROSTVAC-V/F + Ipilimumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/5 (0%)		0/4 (0%)		0/6 (0%)
Other (Not Including Serious) Adverse Events
	Arm A: PROSTVAC-V/F		Arm B: Ipilimumab Monotherapy		Arm C: Combined PROSTVAC-V/F + Ipilimumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	5/5 (100%)		3/4 (75%)		5/6 (83.3%)
Blood and lymphatic system disorders
Anemia	0/5 (0%)	0	0/4 (0%)	0	1/6 (16.7%)	1
Endocrine disorders
Adrenal insufficiency	0/5 (0%)	0	0/4 (0%)	0	1/6 (16.7%)	1
Hypothyroidism	0/5 (0%)	0	0/4 (0%)	0	1/6 (16.7%)	1
Gastrointestinal disorders
Abdominal distension	0/5 (0%)	0	1/4 (25%)	1	0/6 (0%)	0
Diarrhea	0/5 (0%)	0	1/4 (25%)	1	0/6 (0%)	0
Ileus	0/5 (0%)	0	1/4 (25%)	1	0/6 (0%)	0
Nausea	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Pancreatitis	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Vomiting	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
General disorders
Fatigue	2/5 (40%)	3	2/4 (50%)	2	2/6 (33.3%)	2
Injection site reaction	3/5 (60%)	6	0/4 (0%)	0	3/6 (50%)	5
Fever	3/5 (60%)	3	1/4 (25%)	1	0/6 (0%)	0
Chills	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Edema limbs	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Flu like symptoms	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
General disorders and administration site conditions - Other	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Pain	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Infections and infestations
Urinary tract infection	2/5 (40%)	2	0/4 (0%)	0	0/6 (0%)	0
Investigations
Lipase increased	2/5 (40%)	3	0/4 (0%)	0	0/6 (0%)	0
Serum amylase increased	2/5 (40%)	2	0/4 (0%)	0	0/6 (0%)	0
Blood bilirubin increased	0/5 (0%)	0	0/4 (0%)	0	1/6 (16.7%)	1
Weight gain	0/5 (0%)	0	0/4 (0%)	0	1/6 (16.7%)	1
Metabolism and nutrition disorders
Hypocalcemia	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Hyponatremia	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Musculoskeletal and connective tissue disorders
Back pain	0/5 (0%)	0	1/4 (25%)	1	0/6 (0%)	0
Pain in extremity	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Nervous system disorders
Dizziness	0/5 (0%)	0	0/4 (0%)	0	1/6 (16.7%)	1
Headache	0/5 (0%)	0	0/4 (0%)	0	1/6 (16.7%)	3
Renal and urinary disorders
Urinary incontinence	2/5 (40%)	2	1/4 (25%)	1	2/6 (33.3%)	2
Urinary frequency	0/5 (0%)	0	0/4 (0%)	0	2/6 (33.3%)	2
Urinary urgency	0/5 (0%)	0	1/4 (25%)	1	0/6 (0%)	0
Acute kidney injury	1/5 (20%)	1	0/4 (0%)	0	0/6 (0%)	0
Reproductive system and breast disorders
Erectile dysfunction	1/5 (20%)	1	0/4 (0%)	0	2/6 (33.3%)	2
Skin and subcutaneous tissue disorders
Rash maculo-papular	0/5 (0%)	0	0/4 (0%)	0	1/6 (16.7%)	2
Pruritus	0/5 (0%)	0	1/4 (25%)	2	1/6 (16.7%)	1
Skin and subcutaneous tissue disorders - Other	0/5 (0%)	0	1/4 (25%)	1	2/6 (33.3%)	2
Vascular disorders
Hot flashes	1/5 (20%)	1	0/4 (0%)	0	1/6 (16.7%)	1

Limitations/Caveats

Study was terminated early due to low accrual, thus outcomes are not sufficiently powered for statistical significance.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.